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Background: Minimally invasive distal pancreatectomy decreases time to functional recovery compared
with open distal pancreatectomy, but the cost-effectiveness and impact on disease-specific quality of life
have yet to be established.
Methods: The LEOPARD trial randomized patients to minimally invasive (robot-assisted or laparo-
scopic) or open distal pancreatectomy in 14 Dutch centres between April 2015 and March 2017. Use
of hospital healthcare resources, complications and disease-specific quality of life were recorded up
to 1 year after surgery. Unit costs of hospital healthcare resources were determined, and cost-effectiveness
and cost–utility analyses were performed. Primary outcomes were the costs per day earlier functional
recovery and per quality-adjusted life-year.
Results: All 104 patients who had a distal pancreatectomy (48 minimally invasive and 56 open) in the
trial were included in this study. Patients who underwent a robot-assisted procedure were excluded from
the cost analysis. Total medical costs were comparable after laparoscopic and open distal pancreatectomy
(mean difference €–427 (95 per cent bias-corrected and accelerated confidence interval €–4700 to 3613;
P= 0⋅839). Laparoscopic distal pancreatectomy was shown to have a probability of at least 0⋅566 of
being more cost-effective than the open approach at a willingness-to-pay threshold of €0 per day of
earlier recovery, and a probability of 0⋅676 per additional quality-adjusted life-year at a willingness-to-pay
threshold of €80 000. There were no significant differences in cosmetic satisfaction scores (median 9
(i.q.r. 5⋅75–10) versus 7 (4–8⋅75); P=0⋅056) and disease-specific quality of life after minimally invasive
(laparoscopic and robot-assisted procedures) versus open distal pancreatectomy.
Conclusion: Laparoscopic distal pancreatectomy was at least as cost-effective as open distal pancreatec-
tomy in terms of time to functional recovery and quality-adjusted life-years. Cosmesis and quality of life
were similar in the two groups 1 year after surgery.
∗The LEOPARD trial collaborators are also co-authors of this article and can be found under the heading Collaborators
Paper accepted 1 February 2019
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Introduction
Minimally invasive distal pancreatectomy has gained
popularity in recent years. Meta-analyses1,2 of non-
randomized, mostly single-centre and/or retrospective
studies have suggested a decreased length of hospital
stay after minimally invasive compared with open distal
pancreatectomy. Recently, the multicentre randomized
LEOPARD trial3 showed a 2-day reduction in time to
functional recovery and duration of hospital stay in favour
of minimally invasive distal pancreatectomy compared
with the open approach. Despite these positive results, the
costs associated with minimally invasive surgery could be
a barrier to further implementation4.
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Data on the costs of minimally invasive distal pancrea-
tectomy are limited. One systematic review5 combined data
from 12 small retrospective studies, and showed that intra-
operative costs were higher for minimally invasive distal
pancreatectomy. In eight of these studies, the higher costs
were compensated for by lower postoperative costs. Health
economic data on minimally invasive distal pancrea-
tectomy are even scarcer. Tax and colleagues6 proposed
a decision analytical model, which estimated minimally
invasive distal pancreatectomy to be more cost-effective
than the open approach with a willingness-to-pay thresh-
old of €80 000 for each quality-adjusted life-year (QALY)
gained. In this study, the probabilities of complications
were derived from the literature and expert opinion.
Gurusamy and co-workers7 reported a probability
of 0⋅70–0⋅80 that laparoscopic distal pancreatec-
tomy was cost-effective (willingness-to-pay threshold
€23 163–34 744; £20 000–30 000, exchange rate 10 March
2019); however, this analysis included only patients with
pancreatic cancer, whereas a large proportion of patients
undergoing distal pancreatectomy have other conditions
such as pancreatic cysts.
Data on disease-specific quality of life (QoL) after mini-
mally invasive distal pancreatectomy are also limited. The
LEOPARD trial3 showed improved disease-specific QoL
after minimally invasive distal pancreatectomy from day
3 to day 30 after surgery. Quality-of-life outcomes after
minimally invasive distal pancreatectomy beyond this time
point and data on more specific measures, such as cosmetic
satisfaction, are not currently available.
Therefore, the aim of the present study was to undertake
an economic evaluation, and to analyse QoL after mini-
mally invasive versus open distal pancreatectomy using data
from the multicentre LEOPARD trial up to 1 year after
surgery.
Methods
LEOPARD trial
This economic evaluation was performed alongside
the multicentre patient-blinded randomized LEOPARD
trial which was approved by the institutional review board
of Amsterdam UMC, location AMC, University of Am-
sterdam (NTR5188). The rationale and design of this
trial8 and the 90-day follow-up3 have been reported
previously. In summary, patients with a benign, prema-
lignant or malignant tumour of the pancreatic tail were
randomized to undergo either minimally invasive (laparo-
scopic or robot-assisted) or open distal pancreatectomy.
In accordance with the protocol, costs of robot-assisted
procedures were not included, so patients whose procedure
was robot-assisted were excluded from the cost analysis8.
Postoperative outcomes of patients randomized in 14 cen-
tres in the Netherlands were assessed. The primary clinical
endpoint was time to functional recovery, defined as all of
the following: independently mobile to the preoperative
level, sufficient pain control with only oral medication,
ability to maintain more than 50 per cent daily required
calorie intake, no intravenous fluid administration and no
clinical signs of infection. Median time to functional recov-
ery in the LEOPARD trial3 was 4 (i.q.r. 3–6) days after
minimally invasive distal pancreatectomy compared with 6
(5–8) days after open distal pancreatectomy (P< 0⋅001).
Type of economic evaluation, perspective and time
horizon
The economic evaluation was performed as cost-
effectiveness and cost–utility analyses from a hospital
healthcare perspective in a secondary care setting, with a
time horizon of 1 year. The cost-effectiveness endpoint
was the cost per day reduction in duration of postopera-
tive functional recovery. The cost–utility endpoint was
the cost per QALY. The results are reported in accordance
with CHEERS guidelines9,10.
Hospital resources, unit costing and costs
During the 12months after randomization, use of hos-
pital healthcare resources was collected from case report
forms, and electronic hospital information systems: ini-
tial duration of hospital admission (general ward and ICU)
and readmission, surgical (distal pancreatectomy and reop-
erations), radiological (X-ray, ultrasound imaging, CT,
MRI, interventions) and endoscopic (gastroscopy, feeding
tube placement, endoscopic retrograde cholangiopancrea-
tography) procedures, outpatient clinic visits and emer-
gency room visits. The 2015 Dutch manual for costing
in healthcare research11 was used to obtain the unit costs of
hospital admissions, and outpatient and emergency room
visits. The unit costs of radiological and endoscopic pro-
cedures (including personnel, material and overhead costs)
were based on the Amsterdam UMC, location AMC, tar-
iffs ledger. Unit costs of laparoscopic and open distal
pancreatectomy were calculated from costs of operating
theatre use, personnel (specialists’ fees for the surgeon
(total duration of surgery), anaesthetist (estimated involve-
ment for 1 h) and theatre room personnel (total duration
of surgery)), purchase of disposable materials used and
overhead costs. All distal pancreatectomies were planned
electively and were therefore done during office hours. A
fraction of the reoperations were possibly undertaken -
outside office hours, but prices were not adjusted as no
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Table 1 Unit costs of major resources used
Unit Unit costs in 2016 (€) Source
Surgery
Personnel and theatre costs Minute 12⋅22 DCM – 201511/Silver Cross Price finder 201712
Anaesthetist Procedure 114⋅01 DCM – 201511
Laparoscopy tools Procedure 251⋅77 Provider/expert opinion
Epidural Procedure 559⋅49 Hospital ledger 2014
Wound catheters Procedure 60⋅0 Expert opinion
Reoperation Procedure 1591⋅90 Hospital ledger 2014
Hospital stay
General ward Day 577⋅50 DCM – 201511*
ICU Day 2033⋅14 DCM – 201511*
Diagnostic procedures
CT Procedure 189⋅08 Hospital ledger 2014
MRI Procedure 435⋅66 Hospital ledger 2014
Ultrasound imaging Procedure 142⋅81 Hospital ledger 2014
Radiography of thorax/abdomen Procedure 48⋅75 Hospital ledger 2014
Therapeutic procedures
ERCP or drainage Procedure 689⋅54 Hospital ledger 2014
Radiological drainage Procedure 902⋅67 Hospital ledger 2014
Vascular embolization Procedure 1822⋅42 Hospital ledger 2014
Endoscopic feeding tube Procedure 302⋅84 Hospital ledger 2014
Diagnostic endoscopy Procedure 288⋅39 Hospital ledger 2014
Peripherally inserted central catheter Procedure 546⋅79 Hospital ledger 2014
*Adjusted for academic or non-academic hospital admissions. DCM, Dutch cost manual; ERCP, endoscopic retrograde cholangiopancreatography.
differences between minimally invasive and open proced-
ures were expected for this. Unit costs were calculated for
the reference year 2016, after price indexing with general
consumer price indices if original sources from other base
years were used (https://www.cbs.nl/; accessed 1 Decem-
ber 2017) (Table 1). Costs were calculated as the product of
the numbers of hospital resources used and their respective
unit costs. All costs are presented in euros.
Postoperative outcomes
All postoperative outcomes up to 1 year after surgery
were registered on a standard case report form. Compli-
cations were classified according to the Clavien–Dindo
classification13 and those of grade III or higher were
considered clinically relevant. Pancreatic surgery-specific
complications (delayed gastric emptying, postoperative
pancreatic fistula and postpancreatectomy haemorrhage)
were classified according to International Study Group of
Pancreatic Surgery definitions14–16.
Quality-adjusted life-years and quality-of-life
analysis
The EuroQol Five dimensions (EQ-5D™; EuroQol
Group, Rotterdam, the Netherlands)17 and European
Organization for Research and Treatment of Cancer
(EORTC) core Quality of Life Questionnaire QLQ-C3018
were completed by patients before surgery (baseline), and
1, 3, 5, 14, 30, 90 and 365 days after operation. An exten-
sive follow-up questionnaire was sent on day 365 after
surgery. This questionnaire concerned patient character-
istics (current height and weight), wound complications,
wound complaints and satisfaction regarding the cosmetic
result. This questionnaire also included the EORTC
QLQ-PAN26 questionnaire. The EQ-5D™ was used to
derive QALYs, whereas the QLQ-C30 and QLQ-PAN26
described disease-specific QoL. QoL outcomes during the
first 90 days after surgery have been reported previously3.
Each patient was asked to score five aspects of health
status using the EQ-5D™ questionnaire: mobility,
self-care, usual activities, pain/complaints and mood
(anxiety/depression). A patient could indicate for each
dimension whether they experienced no, some or serious
problems. During the study, the EuroQol Group pre-
sented the EQ-5D-5L™ questionnaire as the improved
version of the EQ-5D-3L™, with five instead of three
response levels for each item. Therefore, at 1 year after
surgery patients received the EQ-5D-5L™ questionnaire.
Cross-walk value sets were used to map EQ-5D-5L™
scores to EQ-5D-3L™ scores. EQ-5D-3L™ health status
scoring profiles were converted into health utilities by
© 2019 The Authors. BJS published by John Wiley & Sons Ltd www.bjs.co.uk BJS 2019; 106: 910–921
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Fig. 1 Study flow chart
Included in 1-year follow-up
and cost analysis
n=104
Excluded n=4
 Intraoperative metastases n=3
 Laparoscopic adrenalectomy n=1
Open distal
pancreatectomy group
n=56
Minimally invasive distal
pancreatectomy group
n=48
Included in QoL
analysis
n=33
Included in QoL
analysis
n=30
LEOPARD trial
n=108
Excluded n=23
 Died within 1 year n=3
 Did not return follow-up
 questionnaire n=20
Excluded n=18
 Died within 1 year n=4
 Did not return follow-up
 questionnaire n=14
QoL, quality of life.
applying an existing health valuation algorithm based on
a time trade-off technique to elicit preferences from the
Dutch general population19. Where EQ-5D™ health
status scoring profiles were missing at any time point,
health utilities were derived by taking the mean of ten
imputations following predictive mean matching before
calculation of QALYs. Patients who died were assigned
a health utility of zero for the remainder of follow-up.
QALYs were calculated from the area under the curve
of health utility values during the first year following
interpolation between successive measurements over time.
The QLQ-C30 questionnaire is a cancer-specific meas-
urement instrument focusing on several aspects of QoL,
including physical, emotional and social functioning. The
global health score was reported for the present study.
TheQLQ-PAN26 is a pancreatic cancer-specific extension
to the QLQ-C30 focusing on specific symptoms related
to pancreatic disease (pancreatic pain, digestive problems,
altered bowel habit, hepatic pain, body image, health-
care satisfaction and sexuality). Missing QLQ-C30 and
QLQ-PAN26 data were imputed ten times after predictive
mean matching.
Statistical analysis
Analyses were performed according to modified intention-
to-treat principles, excluding patients who did not undergo
Table 2 Baseline characteristics
MIS
(n=48)
Open
(n=56) P†
Age (years)* 61(13) 63(12) 0⋅495‡
Sex ratio (F :M) 19 : 29 29 : 27 0⋅213
BMI (kg/m)2* 27(6) 26(4) 0⋅825‡
History of abdominal surgery 20 (42) 27 (48) 0⋅504
History of diabetes mellitus 5 (10) 10 (18) 0⋅282
History of pancreatitis 3 (6) 3 (5) 1⋅000§
ASA physical status grade 0⋅571
I 12 (25) 9 (16)
II 29 (60) 37 (66)
III 7 (15) 10 (18)
Values in parentheses are percentages unless indicated otherwise; *values
are mean(s.d.). MIS, minimally invasive distal pancreatectomy; open, open
distal pancreatectomy. †χ2 test, except ‡independent-samples t test and
§Fisher’s exact test.
distal pancreatectomy owing to metastases or tumour loca-
tion. Categorical variables were compared using the χ2 or
Fisher’s exact test, as appropriate. Independent-samples t
test was used for analysis of normally distributed continu-
ous variables and theMann–WhitneyU test for those with
a skewed distribution.
Differences in QLQ-C30 and QLQ-PAN26
scores between minimally invasive and open distal
© 2019 The Authors. BJS published by John Wiley & Sons Ltd www.bjs.co.uk BJS 2019; 106: 910–921
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Table 3 Resource utilization and mean costs per patient, indexed for 2016
Laparoscopic distal
pancreatectomy (n= 43)
Open distal
pancreatectomy (n=56)
Unit Mean units Costs (€)* Mean units Costs (€)*
Difference
in costs (€)
Surgery Procedure 1 5081 (4666, 5497) 1 4043 (3778, 4307) 1038 (527, 1531)
Admission 6517 (4868, 8363) 8549 (6242, 11692) –2032 (–5840, 1130)
Surgical ward Days 11⋅4 5950 (4486, 7671) 12⋅1 6806 (5419, 8394) –857 (–3206, 1547)
ICU Days 1⋅7 567 (144, 1147) 4 1743 (489, 3681) –1175 (–3796, 435)
After discharge 841 (680, 1002) 600 (481, 724) 239 (28, 438)
Outpatient clinic Visit 4⋅7 628 (524, 736) 3⋅6 489 (410, 571) 139 (3, 275)
Emergency room Visit 0⋅8 213 (131, 305) 0⋅4 112 (62, 170) 101 (–6, 208)
Imaging Procedures 3⋅5 647 (473, 829) 3⋅2 500 (390, 618) 147 (–82, 359)
Reinterventions Procedures 1⋅4 1118 (507, 1853) 1⋅3 938 (504, 1478) 181 (–648, 1010)
Total costs 14204 (11 992, 16 714) 14 631 (11 694, 18 508) –427 (–4700, 3616)
*Values are mean (95 per cent bias-corrected and accelerated confidence intervals) costs estimated by non-parametric bootstrapping.
Fig. 2 Distribution of costs
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pancreatectomy groups over time, adjusted for base-
line values, were assessed using a generalized linear
mixed model with pooling of data from the imputation
sets.
Differences in health economic outcomes between
laparoscopic and open distal pancreatectomy were ana-
lysed by means of non-parametric bootstrapping, drawing
5000 samples of the same sizes as the original samples,
with replacement20. Mean differences are reported with
corresponding 95 per cent bias-corrected and accelerated
confidence intervals (BCaCI); mean rather than median
values are considered appropriate in health economic
evaluations. The incremental cost-effectiveness ratio
for laparoscopic versus open distal pancreatectomy was
calculated as the difference in mean costs per patient
divided by the mean gain per patient in reduction in time
to functional recovery measured in days. The incremental
cost–utility ratio was calculated as the difference in mean
costs per patient divided by the difference in mean QALYs
per patient. Results were visualized in a cost-effectiveness
plane. Cost-effectiveness acceptability curves were
prepared showing the probability of laparoscopic dis-
tal pancreatectomy being cost-effective for various levels
of societal willingness to pay per day reduction in time to
functional recovery and per QALY gained.
P< 0⋅050 was considered statistically significant. All ana-
lyses were performed in SPSS® Windows® version 24.0
(IBM, Armonk, New York, USA).
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Fig. 3 Cost-effectiveness analysis
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a Cost-effectiveness plane showing differences in hospital healthcare costs and in time until recovery between laparoscopic and open distal pancreatectomy.
There are four possible outcomes: the laparoscopic approach is more costly and more effective (upper right quadrant), more costly and less effective (upper
left), cheaper and less effective (lower left), or cheaper and more effective (lower right). b Cost-effectiveness acceptability curve showing the probability of
laparoscopic distal pancreatectomy being cost-effective for different values of willingness to pay per day of earlier recovery.
Fig. 4 Cost–utility analysis
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a Cost-effectiveness plane showing differences in hospital healthcare costs and in quality-adjusted life-years (QALYs) between laparoscopic and
open distal pancreatectomy. There are four possible outcomes: the laparoscopic approach is more costly and more effective (upper right quadrant),
more costly and less effective (upper left), cheaper and less effective (lower left), or cheaper and more effective (lower right). b Cost-effectiveness
acceptability curve showing the probability of laparoscopic distal pancreatectomy being cost-effective for different values of willingness to pay per
additional QALY.
Results
In total, 104 patients underwent distal pancreatectomy
in the LEOPARD trial and were included in the present
analysis (Fig. 1). One patient in the minimally invasive dis-
tal pancreatectomy group underwent an open procedure.
This patient was analysed in the minimally invasive group
according to the intention-to-treat principle. Baseline
characteristics were comparable in the two groups (Table 2).
Cost analysis and cost-effectiveness
Five patients who had robot-assisted surgery were excluded
from the analyses of cost and cost-effectiveness, according
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Table 4 Postoperative complications up to 1 year
Minimally invasive distal
pancreatectomy (n=48)
Open distal
pancreatectomy (n=56) P†
Clavien–Dindo grade≥ III 18 (38) 21 (38) 1⋅000‡
IIIa + IIIb 16 (33) 16 (29)
IVa+Vb 2 (4) 5 (9)
Reintervention 18 (38) 21 (38) 1⋅000‡
Surgical 2 (4) 3 (5) 1⋅000
Postoperative pancreatic fistula grade B/C 21 (44) 14 (25) 0⋅044‡
Grade B 18 (38) 13 (23)
Grade C 3 (6) 1 (2)
Percutaneous catheter drainage 12 (25) 12 (21) 0⋅667‡
Endoscopic drainage 6 (13) 6 (11) 1⋅000
Drainage>90days after surgery 4 (8) 2 (4) 0⋅411
Delayed gastric emptying grade 4 (8) 11 (20) 0⋅101
Postpancreatectomy haemorrhage grade B/C 2 (4) 2 (4) 1⋅000
Readmission 17 (35) 15 (27) 0⋅342‡
Total duration of hospital stay (days)* 6 (5–14) 8 (6–14) 0⋅055§
Death within 1 year 4 (8) 3 (5) 0⋅701
Symptomatic incisional hernia 0 (0) 2 (4) 0⋅498
New-onset diabetes mellitus 12 (25) 6 (11) 0⋅070
Pancreatic enzyme supplementation 9 (19) 6 (11) 0⋅275
Values in parentheses are percentages unless indicated otherwise; *values are median (i.q.r.). †Fisher’s exact test, except ‡χ2 test and §Mann–Whitney U
test.
Table 5 Cosmetic satisfaction
Minimally invasive distal
pancreatectomy (n= 30)
Open distal
pancreatectomy (n= 33) P‡
Satisfaction with cosmetic result* 9 (5⋅5–10) 7 (4–8⋅75) 0⋅056
No. of patients visiting physician owing to problems with scar 5 4 0⋅728§
Chronic pain associated with scar†
At rest 0 (0–0) 0 (0–1) 0⋅433
During movement 0 (0–1) 0 (0–1⋅75) 0⋅993
During coughing/lifting heavy objects 0 (0–0⋅5) 0 (0–2⋅75) 0⋅259
Effect on daily activities 0 (0–0⋅25) 0 (0–0) 0⋅426
Values are median (range) unless indicated otherwise. *Scored on a scale from 0 (completely unsatisfied) to 10 (completely satisfied); †scored on a scale
from 0 (no pain) to 10 (severe pain). ‡Mann–Whitney U test, except §Fisher’s exact test.
to the protocol. Mean use of hospital resources and costs
per patient for laparoscopic and open distal pancrea-
tectomy, as well as mean cost differences, are shown
in Table 3 and Fig. 2. Mean total costs were €14 204 (95
per cent BCaCI €11 992 to 16 714) for laparoscopic and
€14 631 (11 694 to 18 508) for open distal pancreatec-
tomy; the mean difference was €–427 (–4700 to 3613)
(P= 0⋅839). Mean time to functional recovery was 6⋅37
(95 per cent BCaCI 4⋅72 to 8⋅52) days after laparoscopic
and 8⋅05 (6⋅57 to 9⋅87) days after open distal pancreate-
ctomy, with a mean difference of –1⋅68 (–4⋅40 to 1⋅29)
days (P= 0⋅271). Fig. 3a shows the differences in hospital
healthcare costs according to days of earlier recovery of
the 5000 bootstrap samples. In 54⋅9 per cent of bootstraps,
costs of laparoscopic distal pancreatectomy were lower
and the laparoscopic approach reduced the time to func-
tional recovery (lower right quadrant). In 11⋅5 per cent, the
laparoscopic procedure was more expensive and resulted in
a longer time to functional recovery (upper left quadrant).
In 1⋅7 per cent, laparoscopic distal pancreatectomy was
cheaper, but resulted in a longer time to functional recov-
ery, whereas in 31⋅8 per cent it was more expensive but
resulted in earlier recovery. Fig. 3b shows the probability
of laparoscopic distal pancreatectomy being cost-effective
for different values of societal willingness to pay per day
reduction in time to recovery; at a willingness-to-pay
threshold of €0, the probability was 0⋅566, and at €2000 it
was 0⋅786.
© 2019 The Authors. BJS published by John Wiley & Sons Ltd www.bjs.co.uk BJS 2019; 106: 910–921
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Fig. 5 Quality-of-life analysis
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Quality-adjusted life-years and cost–utility
The five patients who underwent robot-assisted surgery
were also excluded from the cost–utility analysis. The
mean number of QALYs generated was 0⋅810 (95 per cent
BCaCI 0⋅766 to 0⋅850) for laparoscopic and 0⋅792 (0⋅736
to 0⋅839) for open distal pancreatectomy, with a mean
difference of 0⋅018 (–0⋅046 to 0⋅082) (P= 0⋅609). Fig. 4a
shows the differences in hospital healthcare costs accord-
ing to QALYs in the 5000 bootstrap samples. In 45⋅2
per cent of bootstraps, laparoscopic distal pancreatectomy
decreased costs and increased QALYs (lower right quad-
rant). In 18⋅4 per cent, laparoscopy was more expen-
sive and decreased QALYs (upper left quadrant). In 11⋅4
per cent, costs of laparoscopic distal pancreatectomy were
lower, but laparoscopy resulted in fewer QALYs, whereas
in 25⋅0 per cent laparoscopic distal pancreatectomy was
more expensive but resulted in more QALYs. Fig. 4b shows
the probability of laparoscopic distal pancreatectomy being
cost-effective for different values of societal willingness to
pay per additional QALY; at a willingness-to-pay threshold
of €80 000, the probability was 0⋅676.
Postoperative complications
Postoperative complications up to 1 year after mini-
mally invasive or open distal pancreatectomy are shown
in Table 4. Complications of at least Clavien–Dindo grade
III, reinterventions and readmissions were all compara-
ble between groups. Twenty-one patients (44 per cent)
developed a grade B/C pancreatic fistula in the minimally
invasive group, compared with 14 (25 per cent) in the
open group (P= 0⋅044); this included one late grade B/C
pancreatic fistula (more than 90 days after surgery) in each
group. In contrast, rates of percutaneous (12 (25 per cent)
versus 12 (21 per cent); P= 0⋅667) and endoscopic (6 (13
per cent) versus 6 (11 per cent); P= 1⋅000) catheter drainage
for pancreatic fistula were comparable between groups.
The total duration of hospital stay, including readmissions
during 1 year after surgery, was 6 (i.q.r. 5–14) and 8 (6–14)
days after minimally invasive and open distal pancreatec-
tomy respectively (P= 0⋅055). The mortality rate was
comparable in the two groups. During 1-year follow-up,
four patients (8 per cent) died in the minimally invasive
group and three (5 per cent) in the open group (P= 0⋅701).
One patient in the minimally invasive group died from
ventricular fibrillation which caused cerebral ischaemia;
the others all had a malignant tumour and died from recur-
rent disease or metastasis. Asymptomatic incisional hernia
did not occur after minimally invasive distal pancrea-
tectomy, but was diagnosed in two patients (4 per cent)
after an open procedure (P= 0⋅498). Surgical hernia repair
was not performed. New-onset diabetes was diagnosed in
12 patients (25 per cent) after minimally invasive and six
(11 per cent) after open pancreatectomy (P= 0⋅070). Nine
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(19 per cent) and six (11 per cent) patients respectively used
oral pancreatic enzyme supplements after pancreatectomy
(P= 0⋅275).
Oncological outcomes
Of all included patients, 20 (19⋅2 per cent) were diag-
nosed with a pancreatic ductal adenocarcinoma: 11 (23
per cent) in the minimally invasive group and nine (16
per cent) in the open group. Five of these patients died
from local recurrence or metastasis within 1 year of surgery
(minimally invasive 2 of 11, open 3 of 9; P= 0⋅617).
Six of 11 patients received chemotherapy after minimally
invasive and five of nine after open distal pancreatectomy
(P= 1⋅000).
Quality of life
Disease-specificQoL questionnaires were completed by 63
of 97 patients (65 per cent) who were still alive. The
median cosmetic satisfaction score regarding scars was 9
(i.q.r. 5⋅5–10) after minimally invasive and 7 (4–8⋅75)
after open distal pancreatectomy (P= 0⋅056), on a scale
from 0 to 10. Self-reported chronic pain scores associated
with the scar were low and comparable between groups
(Table 5). The QLQ-C30 global health score and the seven
categories scored using the PAN-26 questionnaire were all
comparable 1 year after minimally invasive and open distal
pancreatectomy (Fig. 5).
Discussion
In the LEOPARD trial, laparoscopic distal pancreatectomy
had a probability of 0⋅566 of being more cost-effective
than the open procedure at a willingness-to-pay threshold
of €0 per day earlier functional recovery. The probabil-
ity per additional QALY was 0⋅676 at a willingness-to-pay
threshold of €80 000. Measures of disease-specific QoL
were comparable for minimally invasive and open dis-
tal pancreatectomy. Follow-up of complications showed
more grade B/C pancreatic fistula in the minimally invasive
group than the open group, whereas the rates of endoscopic
and catheter drainage were similar. Wound complications
(incisional hernia, infections, pain) were rare after mini-
mally invasive and open distal pancreatectomy, and com-
parable between groups.
The findings of the present study are largely in line with
the available data on costs and cost-effectiveness in laparo-
scopic versus open distal pancreatectomy, but also in other
types of laparoscopic surgery6,7,21. To be able to inter-
pret the cost-effectiveness probabilities, more informa-
tion regarding the societal willingness-to-pay threshold for
earlier recovery is needed. The cost-effectiveness accept-
ability curve (Fig. 3b) shows that, if society were not willing
to pay for earlier recovery, laparoscopic distal pancreate-
ctomy would be cost-effective in only slightly more than
half of all patients undergoing this procedure. Therefore,
strategies to improve identification of patients who will
benefit most should be investigated, and further studies
should also focus on the cost-effectiveness of robot-assisted
distal pancreatectomy.
Although minimally invasive distal pancreatectomy may
be the preferable treatment option from a health economic
perspective, the higher rate of grade B/C pancreatic
fistula in the minimally invasive group is concerning,
and has not been reported previously. In the LEOPARD
trial3, during the first 90 days after surgery, there was
a trend towards a higher rate of grade B/C pancreatic
fistula in the minimally invasive compared with the open
group, whereas the rates of increased drain amylase levels
on day 3 and number of percutaneous catheter drainage
procedures were similar. These findings could be explained
by more patients being discharged home with the surgi-
cal drain still in place after minimally invasive distal
pancreatectomy (owing to faster postoperative recovery),
resulting in drain removal being delayed for more than
21 days after surgery. A higher rate of grade B/C pancreatic
fistula could lead to more reinterventions and outpatient
clinic visits, and a longer hospital stay, with increased
costs; however, this was not observed in the present anal-
ysis, strengthening the abovementioned hypothesis. It
should be noted that the LEOPARD trial was not powered
to show differences in postoperative complications and that
studies including 1-year follow-up of complications after
distal pancreatectomy are limited. The DISPACT 2 trial22,
which is currently in progress, is comparing laparoscopic
and open distal pancreatectomy with the comprehensive
complication index as primary outcome and may give more
insight.
Improved QoL and cosmetic satisfaction are often
mentioned as a benefit of minimally invasive surgery23–26.
The present study, however, found that QoL and cosmetic
satisfaction were comparable after minimally invasive
and open distal pancreatectomy. During the first 30 days
after surgery in the LEOPARD trial3, superior QoL out-
comes were reported after minimally invasive procedures.
The benefits of minimally invasive over open distal pan-
createctomy are apparently most prominent during the
early phase after surgery (in terms of pain and mobility).
Regarding cosmetic satisfaction, the overall score was
non-significantly higher in the minimally invasive group,
so a type II error cannot be excluded. No standardized and
validated body image questionnaire or cosmetic scale was
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used to assess cosmetic satisfaction. During 2- and 5- year
follow-up, a standardized body image questionnaire was
added to the follow-up questionnaires.
Use of smaller incisions and therefore better preserva-
tion of the abdominal wall is one advantage of minimally
invasive surgery. In another study27, the hernia rate after a
median follow-up of 53months was 5 per cent after mini-
mally invasive and 17⋅4 per cent after open distal pancrea-
tectomy (P= 0⋅050). A systematic review28 of RCTs com-
paring laparoscopic and open abdominal surgery showed a
lower incisional hernia rate in the laparoscopic group after
at least 1 year (4⋅3 versus 10⋅1 per cent). In the present study,
the 1-year rate of incisional hernia was low in both groups.
This could either be related to the lack of a standardized
method for detection of incisional hernias (self-reported
or as a finding during routine physical examination), the
short duration of follow-up, or type (midline versus trans-
verse subcostal) and length of incision. Scar length was
not measured in all patients in the LEOPARD trial, but
the specimens were extracted through a Pfannenstiel inci-
sion in all minimally invasive procedures. Another system-
atic review29 specifically described an increase in hernia
rates after midline laparotomy from 12⋅6 per cent in the
first year after surgery to 22⋅4 per cent in the third year.
Results of 2- and 5-year follow-up are awaited, and future
cost-effectiveness analyses should include the cost of inci-
sional hernia repairs.
The present study has some limitations which should
be kept in mind when interpreting the results. First, the
sample size was not designed to detect a difference in
complication rates. A much larger sample is needed to
analyse differences in overall complications and pancre-
atic fistula rates between groups. Second, no standard-
ized follow-up at the outpatient clinic was performed,
for instance for hernia detection using standard examina-
tion or imaging. This could have led to under-reporting
of postoperative complications such as incisional hernia.
Third, the QLQ-C30 and PAN-26 questionnaires were
designed and validated for use in patients with cancer, but
not all patients included in this study were diagnosed with
cancer, which could have influenced outcomes. Fourth,
the health economic evaluation was performed alongside
an RCT, and restricted to a hospital healthcare perspec-
tive. Although all major cost components were included
in the analysis, more attention should normally be paid
to potential gains from earlier return to work for patients
in employment owing to a quicker recovery following
minimally invasive surgery. Finally, for resource use that
did not differ between groups (such as postsplenectomy
vaccinations), costs were notmeasured owing to the limited
study funding.
Minimally invasive distal pancreatectomy is a promising
healthcare intervention, both from a clinical and a health
economic perspective. Continued follow-up and additional
studies are needed to further analyse long-term compli-
cations and the financial implications for the healthcare
insurer.
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